[HTML][HTML] First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

GJ Morgan, FE Davies, WM Gregory, K Cocks, SE Bell… - The Lancet, 2010 - thelancet.com
Background Bisphosphonates reduce the risk of skeletal events in patients with malignant
bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and …

Aetiology of bone disease and the role of bisphosphonates in multiple myeloma

AJ Ashcroft, FE Davies, GJ Morgan - The lancet oncology, 2003 - thelancet.com
Osteolytic bone disease is a major cause of morbidity in patients with multiple myeloma. Our
understanding of the pathophysiology of multiple myeloma has increased substantially …

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis

FE Davies, AM Dring, C Li, AC Rawstron… - Blood, 2003 - ashpublications.org
To define specific pathways important in the multistep transformation process of normal
plasma cells (PCs) to monoclonal gammopathy of uncertain significance (MGUS) and …

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

AC Rawstron, FE Davies, R DasGupta… - Blood, The Journal …, 2002 - ashpublications.org
Conventional monitoring strategies for myeloma are not sufficiently sensitive to identify
patients likely to benefit from further therapy immediately after transplantation. We have used …

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous …

G Cook, C Williams, JM Brown, DA Cairns… - The lancet …, 2014 - thelancet.com
Background Relapsed multiple myeloma has no standard treatment, and the role of
autologous stem-cell transplantation (ASCT) has not been fully defined. We aimed to …

[HTML][HTML] Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary …

GJ Morgan, JA Child, WM Gregory, AJ Szubert… - The lancet …, 2011 - thelancet.com
Background Bisphosphonates are the standard of care for reducing the risk of skeletal-
related events in patients with bone lesions from multiple myeloma. The MRC Myeloma IX …

CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4CD8αβTCR+ Double Negative T cells are decreased in the peripheral blood of …

S Feyler, M Von Lilienfeld‐Toal… - British journal of …, 2009 - Wiley Online Library
Increased levels of naturally occurring regulatory T cells (TReg cells) have been found in a
variety of solid tumours and haematological malignancies. In multiple myeloma (MM) …

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X …

G Cook, AJ Ashcroft, DA Cairns, CD Williams… - The Lancet …, 2016 - thelancet.com
Summary Background The Myeloma X trial previously reported improved durability of
response (time to disease progression) in patients with relapsed multiple myeloma with …

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX …

GJ Morgan, FE Davies, WM Gregory… - Blood, The Journal …, 2012 - ashpublications.org
Abstract The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examined
traditional and thalidomide-based induction and maintenance regimens and IV zoledronic …

[PDF][PDF] Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin

AJ Ashcroft, SM Cruickshank, PI Croucher, MJ Perry… - Immunity, 2003 - cell.com
Autoimmune associated bone disease and intestinal inflammation are closely linked with
deregulation and hyperactivation of autoreactive CD4 T cells. How these T cells are …